Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial

Ophthalmology

Volumn 123, Issue 6, 2016, Pages 1351-1359

  Wells, John A ^a   Glassman, Adam R ^b   Ayala, Allison R ^b   Jampol, Lee M ^c   Bressler, Neil M ^d   Bressler, Susan B ^d   Brucker, Alexander J ^e   Ferris, Frederick L ^f   Hampton, G Robert ^g   Jhaveri, Chirag ^h   Melia, Michele ^b   Beck, Roy W ^b  

^a Palmetto Retina Center   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g Retina Vitreous Surgeons   (United States)

^h Retina Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; CATARACT; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; INTRAOCULAR HYPERTENSION; LASER COAGULATION; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA TEAR; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC RETINOPATHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTIMODALITY CANCER THERAPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84975698767     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.02.022     Document Type: Article

References (14)

1. L.M. Jampol, A.R. Glassman, and N.M. Bressler Comparative effectiveness trial for diabetic macular edema: three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network JAMA Ophthalmol 133 2015 983 984
2. Diabetic Retinopathy Clinical Research Network J.A. Wells, A.R. Glassman, A.R. Ayala, and et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema N Engl J Med 372 2015 1193 1203
3. Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077 e35
4. D.M. Brown, U. Schmidt-Erfurth, D.V. Do, and et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies Ophthalmology 122 2015 2044 2052
5. Q.D. Nguyen, D.M. Brown, D.M. Marcus, and et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
6. Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
7. J. Schafer Multiple imputation: a primer Statistical Methods in Medical Research 8 1999 3 15
8. D. Spiegelman, and E. Hertzmark Easy SAS calculations for risk or prevalence ratios and differences Am J Epidemiol 162 2005 199 200
9. Westfall PH, Wolfinger RD. Closed multiple testing procedures and PROC MULTITEST. Available at: http://support.sas.com/kb/22/addl/fusion22950-1-multtest.pdf. Accessed February 16, 2016.
10. Comparison of Age-Related Macular Degeneration Trials (CATT) Research Group D.F. Martin, M.G. Maguire, S.L. Fine, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
11. U. Chakravarthy, S.P. Harding, C.A. Rogers, and et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 2013 1258 1267
12. U. Schmidt-Erfurth, P.K. Kaiser, J.F. Korobelnik, and et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 2014 193 201
13. M. Thulliez, D. Angoulvant, M.L. Le Lez, and et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis JAMA Ophthalmol 132 2014 1317 1326
14. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106